bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Fig. 6 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Hierarchical clustering of ESCC and healthy plasma samples
Table S1 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Authors: Girault Isabelle , Adam Julien , Shen Shensi , Roy Séverine , Brard Caroline , Faouzi Sara , Routier Emilie , Lupu Jéremy , Warren Sarah , Sorg Kristina , Ong SuFey , Morel Pascale , Scoazec Jean-Yves , Vagner Stéphan , Robert Caroline
Published: April 2023

Characteristics of the patients
Figure S3 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Authors: Girault Isabelle , Adam Julien , Shen Shensi , Roy Séverine , Brard Caroline , Faouzi Sara , Routier Emilie , Lupu Jéremy , Warren Sarah , Sorg Kristina , Ong SuFey , Morel Pascale , Scoazec Jean-Yves , Vagner Stéphan , Robert Caroline
Published: April 2023

Kaplan Meier representation of the progression-free survival (PFS) and overall survival (OS) for PDL1, CD8, TIS and Melscore variables in all samples (exploratory and validation cohorts) with a recapitulive table of survival medians (NA : Not Available because the 50% survival is not reached)
Figure S1 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Authors: Girault Isabelle , Adam Julien , Shen Shensi , Roy Séverine , Brard Caroline , Faouzi Sara , Routier Emilie , Lupu Jéremy , Warren Sarah , Sorg Kristina , Ong SuFey , Morel Pascale , Scoazec Jean-Yves , Vagner Stéphan , Robert Caroline
Published: April 2023

PD-L1 immunohistochemistry. Positive PD-L1 staining in immune cells (chromogen: diaminobenzidine). PT: peritumoral area, CT: center of the tumor, arrows: areas with dense PD-L1+ immune infiltrate.
Supplementary Table 2 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Mann-Whitney-Wilcoxon analysis of mucin expression comparing normal to PC, High and Low Cellularity to Normal, or High to Low Cellularity
Supplementary Table 1 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Median Expression of Mucins
Figure S3 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Disease and Biological Functions of PC-Based Subtypes
Figure S10 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Expression of mucin splice variants and gemcitabine response.
Supplementary Data from ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
Authors: Verdaguer Helena , Saurí Tamara , Acosta Daniel Alejandro , Guardiola Magdalena , Sierra Alexandre , Hernando Jorge , Nuciforo Paulo , Miquel Josep M. , Molero Cristina , Peiró Sandra , Serra-Camprubí Queralt , Villacampa Guillermo , Aguilar Susana , Vivancos Ana , Tabernero Josep , Dienstmann Rodrigo , Macarulla Teresa
Published: April 2023

Supplementary Data from ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
Supplementary Figure S3 from A MET Targeting Antibody–Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
Authors: Cazes Alex , Betancourt Oscar , Esparza Edgar , Mose Evangeline S. , Jaquish Dawn , Wong Eric , Wascher Alexis A. , Tiriac Hervé , Gymnopoulos Marco , Lowy Andrew M.
Published: April 2023

Post-treatment tumor volumes of PDX1334 grafted tumors
Supplementary Figure S2 from A MET Targeting Antibody–Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
Authors: Cazes Alex , Betancourt Oscar , Esparza Edgar , Mose Evangeline S. , Jaquish Dawn , Wong Eric , Wascher Alexis A. , Tiriac Hervé , Gymnopoulos Marco , Lowy Andrew M.
Published: April 2023

Dose dependent anti-proliferative effect of TR1801-ADC
Supplemental Figure 3 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Authors: Stewart Caitlin M. , Michaud Laure , Whiting Karissa , Nakajima Reiko , Nichols Chelsea , De Frank Stephanie , Hamlin Paul A. , Matasar Matthew J. , Gerecitano John F. , Drullinsky Pamela , Hamilton Audrey , Straus David , Horwitz Steven M. , Kumar Anita , Moskowitz Craig H. , Moskowitz Alison , Zelenetz Andrew D. , Rademaker Jurgen , Salles Gilles , Seshan Venkatraman , Schöder Heiko , Younes Anas , Tsui Dana W.Y. , Batlevi Connie Lee
Published: April 2023

Supplemental Figure S3. A. Waterfall plot based on RECIL criteria. RECIL introduces the minimal response category which is a 10-30% reduction in the sum of longest diameters of target lesions. B. Event-free survival Kaplan-Meier curve.
Supplementary Data from Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Authors: Wei Shiyou , Yin Delong , Yu Shengnan , Lin Xiang , Savani Milan R. , Du Kuang , Ku Yin , Wu Di , Li Shasha , Liu Hao , Tian Meng , Chen Yaohui , Bowie Michelle , Hariharan Seethalakshmi , Waitkus Matthew , Keir Stephen T. , Sugarman Eric T. , Deek Rebecca A. , Labrie Marilyne , Khasraw Mustafa , Lu Yiling , Mills Gordon B. , Herlyn Meenhard , Wu Kongming , Liu Lunxu , Wei Zhi , Flaherty Keith T. , Abdullah Kalil , Zhang Gao , Ashley David M.
Published: April 2023

Supplementary Data from Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Supplementary Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Percent Ivor J. , Babu Sunil , Cultrera Jennifer L. , Mehlhaff Bryan A. , Goodman Oscar B. , Morris David S. , Schnadig Ian D. , Albany Costantine , Shore Neal D. , Sieber Paul R. , Guba Susan C. , Zhang Wei , Wacheck Volker , Donoho Gregory P. , Szpurka Anna M. , Callies Sophie , Lin Boris Kin , Bendell Johanna C.
Published: April 2023

Supplementary Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Supplementary Table 1 from Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Authors: Maura Francesco , Diamond Benjamin , Maclachlan Kylee H. , Derkach Andriy , Yellapantula Venkata D. , Rustad Even H. , Hultcrantz Malin , Shah Urvi A. , Hong Jessica , Landau Heather J. , Iacobuzio-Donahue Christine A. , Papaemmanuil Elli , Irby Shani , Crowley Laura , Crane Michael , Webber Mayris P. , Goldfarb David G. , Zeig-Owens Rachel , Giricz Orsi , Verma Amit , Prezant David J. , Dogan Ahmet , Shah Sohrab P. , Zhang Yanming , Landgren Ola
Published: April 2023

Supplementary Table 1. Baseline patient and disease characteristics with response details in male first responders and recovery workers followed at MSKCC.
Supplementary Figures from Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy
Authors: Peng Shihong , Hu Pan , Xiao Yu-Tian , Lu Weiqiang , Guo Dandan , Hu Shixiu , Xie Jiayi , Wang Minna , Yu Weiwei , Yang Junjie , Chen Huang , Zhang Xiaomin , Zhu Yasheng , Wang Ye , Yang Yue , Zhu Guanghui , Chen Sujun , Wang Jian , Zhang Bo , Chen Weidong , Wu Huangan , Sun Zhenliang , Ding Tao , Zhang Hankun , Yi Zhengfang , Liu Mingyao , Ren Shancheng
Published: April 2023

Supplementary Figures
Supplementary Tables S1-S5 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
Authors: Asleh Karama , Tu Dongsheng , Gao Dongxia , Bramwell Vivien , Levine Mark N. , Pritchard Kathleen I. , Shepherd Lois E. , Nielsen Torsten O.
Published: April 2023

Supplementary Table S1: Patient characteristics in the CCTG MA.5 original trial versus the CCTG MA.5 translational study cohort classifiable by immunohistochemistry; Supplementary Table S2: Patient characteristics in the CCTG MA.12 original trial versus the CCTG MA.12 translational study cohort classifiable by immunohistochemistry; Supplementary Table S3: The distribution of the possible Nestin/INPP4B IHC staining categories in the translational study cohorts of MA.5 and MA.12; Supplementary Table S4: The distribution of the different combinations of nestin/INPP4B IHC staining according to "PAM50 basal-like vs. non basal-like" in MA.5 and MA.12; Supplementary Table S5: Performance characteristics of the IHC basal panel against the intrinsic PAM50 breast cancer subtype assay as a gold standard
Supplementary Figure S1 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
Authors: Asleh Karama , Tu Dongsheng , Gao Dongxia , Bramwell Vivien , Levine Mark N. , Pritchard Kathleen I. , Shepherd Lois E. , Nielsen Torsten O.
Published: April 2023

CONSORT flow diagram depicting the workflow numbers for the cases included in the study translational cohorts from the CCTG MA.5 (A) and CCTG MA.12 (B) clinical trials.
Supplementary Table 2 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Authors: Pizzamiglio Sara , Ciniselli Chiara Maura , Triulzi Tiziana , Gargiuli Chiara , De Cecco Loris , de Azambuja Evandro , Fumagalli Debora , Sotiriou Christos , Harbeck Nadia , Izquierdo Miguel , Nuciforo Paolo , Huober Jens , Cappelletti Vera , Cinieri Saverio , Piccart Martine , Daidone Maria Grazia , Pruneri Giancarlo , Colombo Mario Paolo , Tagliabue Elda , Verderio Paolo , Di Cosimo Serena
Published: April 2023

Table S2. Association of tumor infiltrating immune cells with pathological complete response (pCR) and event free survival (EFS) in TRAR groups.
Supplementary Figure 5 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Authors: Pizzamiglio Sara , Ciniselli Chiara Maura , Triulzi Tiziana , Gargiuli Chiara , De Cecco Loris , de Azambuja Evandro , Fumagalli Debora , Sotiriou Christos , Harbeck Nadia , Izquierdo Miguel , Nuciforo Paolo , Huober Jens , Cappelletti Vera , Cinieri Saverio , Piccart Martine , Daidone Maria Grazia , Pruneri Giancarlo , Colombo Mario Paolo , Tagliabue Elda , Verderio Paolo , Di Cosimo Serena
Published: April 2023

Supplementary Figure S5. Patient-level heatmap of the 27 putative biomarkers assessed in the paper with annotation showing pCR (No; Yes), Event (No; Yes), TRT, Treatment (Combination; Single agent ), ER status (Negative; Positive), TRAR (Low; High), PAM50 subtype (HER2; Other)
Supplementary Figure 4 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Authors: Pizzamiglio Sara , Ciniselli Chiara Maura , Triulzi Tiziana , Gargiuli Chiara , De Cecco Loris , de Azambuja Evandro , Fumagalli Debora , Sotiriou Christos , Harbeck Nadia , Izquierdo Miguel , Nuciforo Paolo , Huober Jens , Cappelletti Vera , Cinieri Saverio , Piccart Martine , Daidone Maria Grazia , Pruneri Giancarlo , Colombo Mario Paolo , Tagliabue Elda , Verderio Paolo , Di Cosimo Serena
Published: April 2023

Supplementary Figure S4. Event-free survival (EFS) probability curve for STAT1. The curve depicts the predicted EFS probability together with the observed pCR responses in the bottom part. Each segment on the abscissa indicates single patientachieving (in green) or not achieving (in red) pCR.
Table S9 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S9
Gene list and mutations of DNA damage repair and drug transporter genes.
Table S8 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S8
Significantly recurrent somatic copy number deletions detected by GISTCIS2
Table S5 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S5
Detailed genetic alterations detected in 11 paired tumor samples sequenced by WES.
Table S3 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S3
Clinical characteristics for the 9 limited-stage SCLCs with paired ctDNA sequencing.
Supplementary Tables from Development and Validation of Machine Learning–based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts
Authors: Chen Kezhong , Nie Yuntao , Park Samina , Zhang Kai , Zhang Yangming , Liu Yuan , Hui Bengang , Zhou Lixin , Wang Xun , Qi Qingyi , Li Hao , Kang Guannan , Huang Yuqing , Chen Yingtai , Liu Jiabao , Cui Jian , Li Mingru , Park In Kyu , Kang Chang Hyun , Shen Haifeng , Yang Yingshun , Guan Tian , Zhang Yaxiao , Yang Fan , Kim Young Tae , Wang Jun
Published: April 2023

Supplementary Tables
Table S13 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S13
KEGG enrichment analysis of genes with acquired mutations in relapsed samples from Wagner's cohort.
Table S12 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S12
Differentially expressed proteins for chemo-resistant and chemo-sensitive human extensive-stage small cell lung cancer samples.
Table S1 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S1
Clinical characteristics for the 11 limited-stage SCLCs receiving chemoradiotherapy.
Supplementary legend from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Supplementary legend
Supplementary legend
Supplementary Table from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer
Authors: Weber Peter , Künstner Axel , Hess Julia , Unger Kristian , Marschner Sebastian , Idel Christian , Ribbat-Idel Julika , Baumeister Philipp , Gires Olivier , Walz Christoph , Rietzler Sibylle , Valeanu Laura , Herkommer Timm , Kreutzer Lisa , Klymenko Olena , Drexler Guido , Kirchner Thomas , Maihöfer Cornelius , Ganswindt Ute , Walch Axel , Sterr Michael , Lickert Heiko , Canis Martin , Rades Dirk , Perner Sven , Berriel Diaz Mauricio , Herzig Stefan , Lauber Kirsten , Wollenberg Barbara , Busch Hauke , Belka Claus , Zitzelsberger Horst
Published: April 2023

Supplementary Table from Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer
Figure S5 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Figure S5
KEGG PI3K-AKT signaling network diagram. Genes with acquired CNVs in more than 2 patients are represented by pink.
Figure S4 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Figure S4
Comparison of somatic point mutation between paired baseline and relapse samples. (A) The changes of number of mutations from treatment-naÃ¯ve to relapsed tissues are shown. The changes of transition, transversion and Indel rate between paired treatment-naÃ¯ve and relapse samples are displayed in (B), (C) and (D), respectively.
Figure S3 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Figure S3
Mutational signatures. The mutational signatures in treatment-naÃ¯ve and relapsed samples are presented in (A) and (B), respectively.
Figure S1 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Figure S1
Somatic copy number variations for regions called by GISTIC2. Copy number deletions and amplifications are showed in (A) and (B), respectively.
Supplementary Table 3 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Authors: Fountzilas Christos , Bajor David L. , Mukherjee Sarbajit , Saltzman Joel , Witkiewicz Agnieszka K. , Maguire Orla , Minderman Hans , Nambiar Ram , Rosenheck Hanna R. , Knudsen Erik S. , Muhitch Jason B. , Abrams Scott I. , Wang Chong , Hutson Alan D. , Attwood Kristopher , Hicks Karen A. , Jurcevic Jennifer A. , Kalinski Pawel , Iyer Renuka , Boland Patrick M.
Published: April 2023

T-cell infiltration for patient LH-01-26 with BRAF V600 mutation in comparison to study population
Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Authors: Li Ning , Bu Hualei , Liu Jihong , Zhu Jianqing , Zhou Qi , Wang Li , Yin Rutie , Wu Xiaohua , Yao Shuzhong , Gu Kangsheng , Zhang Hui , Li Guiling , Pan Hongming , Wu Qiang , An Ruifang , Yang Xinfeng , Zhu Yaping , Wan Xiaoping , Duan Wei , Xiong Jianping , Guo Hongyan , Lou Ge , Wang Jing , Hu Wenjing , Zhang Xin , Meng Yuanguang , Zhang Ben , Wang Yuting , Wang Quanren , Wu Lingying
Published: April 2023

Supplementary Data
Supplementary Figure 5 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Authors: Fountzilas Christos , Bajor David L. , Mukherjee Sarbajit , Saltzman Joel , Witkiewicz Agnieszka K. , Maguire Orla , Minderman Hans , Nambiar Ram , Rosenheck Hanna R. , Knudsen Erik S. , Muhitch Jason B. , Abrams Scott I. , Wang Chong , Hutson Alan D. , Attwood Kristopher , Hicks Karen A. , Jurcevic Jennifer A. , Kalinski Pawel , Iyer Renuka , Boland Patrick M.
Published: April 2023

Changes in peripheral blood immune cell populations on treatment.
Supplementary Figure 4 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Authors: Fountzilas Christos , Bajor David L. , Mukherjee Sarbajit , Saltzman Joel , Witkiewicz Agnieszka K. , Maguire Orla , Minderman Hans , Nambiar Ram , Rosenheck Hanna R. , Knudsen Erik S. , Muhitch Jason B. , Abrams Scott I. , Wang Chong , Hutson Alan D. , Attwood Kristopher , Hicks Karen A. , Jurcevic Jennifer A. , Kalinski Pawel , Iyer Renuka , Boland Patrick M.
Published: April 2023

Multispectral immunofluorescence. Number of cells positive for exhaustion (PD-L1, TIM3, LAG3, CTLA4) and activation markers (OX40) in baseline tumor specimens (A); Quantitation of signals per specimen (B). There are more PDL1 positive tumor cell in the pre-treatment metastatic site biopsy. While there are more activated, partially activated T cell-1 and exhausted T cell-1 in the primary tumor specimens (*p<0.05, ***p<0.001); Changes in different intratumoral cell populations on-treatment (C). Statistics using paired Student T test based on mean value for Matched PIDs Pre Tx Vs Post Tx; Association of baseline number of activated OX40+ cells with PFS (D), and change in activated and partially activated-1 cells with changes in CEA on treatment (E).
Supplementary Figure 1 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Authors: Fountzilas Christos , Bajor David L. , Mukherjee Sarbajit , Saltzman Joel , Witkiewicz Agnieszka K. , Maguire Orla , Minderman Hans , Nambiar Ram , Rosenheck Hanna R. , Knudsen Erik S. , Muhitch Jason B. , Abrams Scott I. , Wang Chong , Hutson Alan D. , Attwood Kristopher , Hicks Karen A. , Jurcevic Jennifer A. , Kalinski Pawel , Iyer Renuka , Boland Patrick M.
Published: April 2023

Consort Diagram.
Supplementary table 2 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Next generation sequencing quality control data, HPViewer read counts and somatic alteration burden
Supplementary table 1 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Number of plasma samples analyzed at each time point
Supplementary figure and table legends from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Legends for supplementary figure and tables
Supplementary fig 4 from A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas
Authors: Yu Shengnan , Wei Shiyou , Savani Milan , Lin Xiang , Du Kuang , Mender Ilgen , Siteni Silvia , Vasilopoulos Themistoklis , Reitman Zachary J. , Ku Yin , Wu Di , Liu Hao , Tian Meng , Chen Yaohui , Labrie Marilyne , Charbonneau Casey M. , Sugarman Eric , Bowie Michelle , Hariharan Seethalakshmi , Waitkus Matthew , Jiang Wen , McLendon Roger E. , Pan Edward , Khasraw Mustafa , Walsh Kyle M. , Lu Yiling , Herlyn Meenhard , Mills Gordon , Herbig Utz , Wei Zhi , Keir Stephen T. , Flaherty Keith , Liu Lunxu , Wu Kongming , Shay Jerry W. , Abdullah Kalil , Zhang Gao , Ashley David M.
Published: April 2023

Supplementary Figure 4. (A-D) The heatmap of significantly expressed gene in M059K, H4, D2224MG and DBTRG-05MG cells treated with or without THIO for 72 hours. |Log2 FC|>2.5 and p<0.05 were chosen as the cut-off value. (E-H) fGSEA table of top 20 up-regulated pathways in M059K and H4 cells treated with or without THIO for 72 hours.
Supplementary Data from Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Authors: Palmer Adam C. , Izar Benjamin , Hwangbo Haeun , Sorger Peter K.
Published: April 2023

Supplementary Data from Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Supplementary Figure S9 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV-αmCD47-G2b is efficacious to treat ovarian cancer in an ID8 immunocompetent metastasis mouse model.
Supplementary Figure S8 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV-αCD47-G1 treatments promote macrophage M1 polarization and NK cell activation in ID8-hCD47 immunocompetent ovarian cancer metastasis mouse model.
Supplementary Table from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Authors: Liu Min , Tayob Nabihah , Penter Livius , Sellars MacLean , Tarren Anna , Chea Vipheaviny , Carulli Isabel , Huang Teddy , Li Shuqiang , Cheng Su-Chun , Le Phuong , Frackiewicz Laura , Fasse Julia , Qi Courtney , Liu Joyce F. , Stover Elizabeth H. , Curtis Jennifer , Livak Kenneth J. , Neuberg Donna , Zhang Guanglan , Matulonis Ursula A. , Wu Catherine J. , Keskin Derin B. , Konstantinopoulos Panagiotis A.
Published: April 2023

Supplementary Table from Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Supplementary Figure S5 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV-αCD47-G1 enhances the therapeutic efficacy in an immunocompetent ovarian cancer metastasis mouse model.
Supplementary Figure S4 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV-αCD47-G1 improves the therapeutic efficacy against ovarian cancer in a xenograft model.
Supplementary Figure S13 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

The concentration of αmCD47 antibody in the bloodstream and at the local tumor sites.
Supplementary Figure S12 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

Anti-viral immune responses after OV-αmCD47-G2b.
Supplementary Figure S11 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV-αmCD47-G2b treatments promote macrophage M1 polarization and NK cell activation in ID8 immunocompetent ovarian cancer metastasis mouse model.
Supplementary Data from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

All supplementary data: supplementary figures s1-s13 and table s1
Supplemental figures from Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity
Authors: Wang Yanping , You Sungyong , Su Shengchen , Yeon Austin , Lo Eric M. , Kim Sungjin , Mohler James L. , Freeman Michael R. , Kim Hyung L.
Published: April 2023

Supplemental figures 1-19 with figure legends
Supplementary Video S1 from A Novel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological and Radiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance
Authors: Dreyfuss Alexandra D. , Goia Denisa , Shoniyozov Khayrullo , Shewale Swapnil V. , Velalopoulou Anastasia , Mazzoni Susan , Avgousti Harris , Metzler Scott D. , Bravo Paco E. , Feigenberg Steven J. , Ky Bonnie , Verginadis Ioannis I. , Koumenis Constantinos
Published: April 2023

Representative video clips of echocardiography performed in unirradiated and irradiated mice 8 weeks post-RT.
Supplementary Data from A Novel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological and Radiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance
Authors: Dreyfuss Alexandra D. , Goia Denisa , Shoniyozov Khayrullo , Shewale Swapnil V. , Velalopoulou Anastasia , Mazzoni Susan , Avgousti Harris , Metzler Scott D. , Bravo Paco E. , Feigenberg Steven J. , Ky Bonnie , Verginadis Ioannis I. , Koumenis Constantinos
Published: April 2023

Supplementary materials and figures
Supplementary Figure from Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Authors: García-Sáenz José Á. , Martínez-Jáñez Noelia , Cubedo Ricardo , Jerez Yolanda , Lahuerta Ainhara , González-Santiago Santiago , Ferrer Nieves , Ramos Manuel , Alonso-Romero Jose L. , Antón Antonio , Carrasco Eva , Chen Jingjing , Neuwirth Rachel , Galinsky Kevin , Vincent Sylvie , Leonard E. Jane , Slamon Dennis
Published: April 2023

Supplementary Figure from Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Authors: Nixon Andrew B. , Sibley Alexander B. , Liu Yingmiao , Hatch Ace J. , Jiang Chen , Mulkey Flora , Starr Mark D. , Brady John C. , Niedzwiecki Donna , Venook Alan P. , Baez-Diaz Luis , Lenz Heinz-Josef , O'Neil Bert H. , Innocenti Federico , Meyerhardt Jeffrey A. , O'Reilly Eileen M. , Owzar Kouros , Hurwitz Herbert I.
Published: April 2023

Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Authors: Nixon Andrew B. , Sibley Alexander B. , Liu Yingmiao , Hatch Ace J. , Jiang Chen , Mulkey Flora , Starr Mark D. , Brady John C. , Niedzwiecki Donna , Venook Alan P. , Baez-Diaz Luis , Lenz Heinz-Josef , O'Neil Bert H. , Innocenti Federico , Meyerhardt Jeffrey A. , O'Reilly Eileen M. , Owzar Kouros , Hurwitz Herbert I.
Published: April 2023

Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Supplementary Data - Table 3 from A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
Authors: Flaig Thomas W. , Tangen Catherine M. , Daneshmand Siamak , Alva Ajjai , Lerner Seth P. , Lucia M. Scott , McConkey David J. , Theodorescu Dan , Goldkorn Amir , Milowsky Matthew I. , Bangs Rick , MacVicar Gary R. , Bastos Bruno R. , Fowles Jared S. , Gustafson Daniel L. , Plets Melissa , Thompson Ian M.
Published: April 2023

Supplemental Table 3 Number of Patients with a Given Type and Grade of Adverse Event Adverse Events Unlikely or Not Related to Treatment Excluded
Supplementary Data from Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Authors: Tully Kathryn M. , Tendler Salomon , Carter Lukas M. , Sharma Sai Kiran , Samuels Zachary V. , Mandleywala Komal , Korsen Joshua A. , Delos Reyes Avelyn Mae , Piersigilli Alessandra , Travis William D. , Sen Triparna , Pillarsetty Nagavarakishore , Poirier John T. , Rudin Charles M. , Lewis Jason S.
Published: April 2023

Supplementary Data from Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Supplementary Table from Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment
Authors: Yaddanapudi Kavitha , Stamp Bryce F. , Subrahmanyam Priyanka B. , Smolenkov Andrei , Waigel Sabine J. , Gosain Rahul , Egger Michael E. , Martin Robert C.G. , Buscaglia Robert , Maecker Holden T. , McMasters Kelly M. , Chesney Jason A.
Published: April 2023

Supplementary Table from Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment
Table S1 and Table S2 from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Authors: Chiorean E. Gabriela , Guthrie Katherine A. , Philip Philip A. , Swisher Elizabeth M. , Jalikis Florencia , Pishvaian Michael J. , Berlin Jordan , Noel Marcus S. , Suga Jennifer M. , Garrido-Laguna Ignacio , Cardin Dana Backlund , Radke Marc R. , Duong Mai , Bellasea Shay , Lowy Andrew M. , Hochster Howard S.
Published: April 2023

Table S1: BROCA-HR gene list Table S2: Best Response, TTP, OS in Patients with HR-DDR Defects
Figure S4 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Figure S4
Supplementary Data from The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
Authors: Manca Paolo , Corallo Salvatore , Busico Adele , Lonardi Sara , Corti Francesca , Antoniotti Carlotta , Procaccio Letizia , Clavarezza Matteo , Smiroldo Valeria , Tomasello Gianluca , Murialdo Roberto , Sartore-Bianchi Andrea , Racca Patrizia , Pagani Filippo , Randon Giovanni , Martinetti Antonia , Sottotetti Elisa , Palermo Federica , Perrone Federica , Tamborini Elena , Prisciandaro Michele , Raimondi Alessandra , Di Bartolomeo Maria , Morano Federica , Pietrantonio Filippo
Published: April 2023

Suppl Fig 5
Supplementary Figure S3 from Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition
Authors: Zhang Pu , Brinton Lindsey T. , Williams Katie , Sher Steven , Orwick Shelley , Tzung-Huei Lai , Mims Alice S. , Coss Christopher C. , Kulp Samuel K. , Youssef Youssef , Chan Wing Keung , Mitchell Shaneice , Mustonen Allison , Cannon Matthew , Phillips Hannah , Lehman Amy M. , Kauffman Tierney , Beaver Larry , Canfield Daniel , Grieselhuber Nicole R. , Alinari Lapo , Sampath Deepa , Yan Pearlly , Byrd John C. , Blachly James S. , Lapalombella Rosa
Published: April 2023

Combined treatment of AR-42 and KPT-9274 leads to mitochondrial potential collapses in cell lines.
Supplementary Figure S2 from Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition
Authors: Zhang Pu , Brinton Lindsey T. , Williams Katie , Sher Steven , Orwick Shelley , Tzung-Huei Lai , Mims Alice S. , Coss Christopher C. , Kulp Samuel K. , Youssef Youssef , Chan Wing Keung , Mitchell Shaneice , Mustonen Allison , Cannon Matthew , Phillips Hannah , Lehman Amy M. , Kauffman Tierney , Beaver Larry , Canfield Daniel , Grieselhuber Nicole R. , Alinari Lapo , Sampath Deepa , Yan Pearlly , Byrd John C. , Blachly James S. , Lapalombella Rosa
Published: April 2023

HDAC8-specific inhibitor (PCI-34051) or AR-42 treatments sensitize AML cell lines to KPT-9274 treatment.
Supplementary Data from Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas
Authors: Momeni-Boroujeni Amir , Dahoud Wissam , Vanderbilt Chad M. , Chiang Sarah , Murali Rajmohan , Rios-Doria Eric V. , Alektiar Kaled M. , Aghajanian Carol , Abu-Rustum Nadeem R. , Ladanyi Marc , Ellenson Lora H. , Weigelt Britta , Soslow Robert A.
Published: April 2023

Supplementary Methods Supplementary Figures S1-S5 Supplementary Tables S1, S2
Table S4 from Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription
Authors: Pang John , Nguyen Nam , Luebeck Jens , Ball Laurel , Finegersh Andrey , Ren Shuling , Nakagawa Takuya , Flagg Mitchell , Sadat Sayed , Mischel Paul S. , Xu Guorong , Fisch Kathleen , Guo Theresa , Cahill Gabrielle , Panuganti Bharat , Bafna Vineet , Califano Joseph
Published: April 2023

Survival analysis of Institutional HPV positive tumors by ecDNA and hybrid classification.
Table S3 from Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription
Authors: Pang John , Nguyen Nam , Luebeck Jens , Ball Laurel , Finegersh Andrey , Ren Shuling , Nakagawa Takuya , Flagg Mitchell , Sadat Sayed , Mischel Paul S. , Xu Guorong , Fisch Kathleen , Guo Theresa , Cahill Gabrielle , Panuganti Bharat , Bafna Vineet , Califano Joseph
Published: April 2023

Survival analysis of TCGA HPV positive tumors by ecDNA and hybrid classification.
Table S1 from Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription
Authors: Pang John , Nguyen Nam , Luebeck Jens , Ball Laurel , Finegersh Andrey , Ren Shuling , Nakagawa Takuya , Flagg Mitchell , Sadat Sayed , Mischel Paul S. , Xu Guorong , Fisch Kathleen , Guo Theresa , Cahill Gabrielle , Panuganti Bharat , Bafna Vineet , Califano Joseph
Published: April 2023

Clinical Data of Institutional Cohort.
Supplementary Legend from Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription
Authors: Pang John , Nguyen Nam , Luebeck Jens , Ball Laurel , Finegersh Andrey , Ren Shuling , Nakagawa Takuya , Flagg Mitchell , Sadat Sayed , Mischel Paul S. , Xu Guorong , Fisch Kathleen , Guo Theresa , Cahill Gabrielle , Panuganti Bharat , Bafna Vineet , Califano Joseph
Published: April 2023

Supplementary Legend
Figure S2 from Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription
Authors: Pang John , Nguyen Nam , Luebeck Jens , Ball Laurel , Finegersh Andrey , Ren Shuling , Nakagawa Takuya , Flagg Mitchell , Sadat Sayed , Mischel Paul S. , Xu Guorong , Fisch Kathleen , Guo Theresa , Cahill Gabrielle , Panuganti Bharat , Bafna Vineet , Califano Joseph
Published: April 2023

Non-canonical virus structures.
Supplementary Table S7 from Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
Authors: Solanki Hitendra S. , Welsh Eric A. , Fang Bin , Izumi Victoria , Darville Lancia , Stone Brandon , Franzese Ryan , Chavan Sandip , Kinose Fumi , Imbody Denis , Koomen John M. , Rix Uwe , Haura Eric B.
Published: April 2023

Supplementary Table S7. The mean-centered CCLE normalized log2 RNA-seq counts for indicated genes and TGFβ-EMT analysis of 15 KRASG12C NSCLC cell lines.
Supplementary Table S4 from Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
Authors: Solanki Hitendra S. , Welsh Eric A. , Fang Bin , Izumi Victoria , Darville Lancia , Stone Brandon , Franzese Ryan , Chavan Sandip , Kinose Fumi , Imbody Denis , Koomen John M. , Rix Uwe , Haura Eric B.
Published: April 2023

Supplementary Table S4. The complete list of identified phosphopeptides after (pY) enrichment and TMT-based quantitative phosphoproteomics analysis in KRASG12C mutant lung cancer cell lines (n=8) with mean-centered log abundance values.
Supplementary Table S1 from Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
Authors: Solanki Hitendra S. , Welsh Eric A. , Fang Bin , Izumi Victoria , Darville Lancia , Stone Brandon , Franzese Ryan , Chavan Sandip , Kinose Fumi , Imbody Denis , Koomen John M. , Rix Uwe , Haura Eric B.
Published: April 2023

Supplementary Table S1. Relative quantification of peptides representing total KRAS, WT KRAS, free KRAS G12C protein and drug bound KRAS G12C Protein Levels.
Supplementary Methods from Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
Authors: Solanki Hitendra S. , Welsh Eric A. , Fang Bin , Izumi Victoria , Darville Lancia , Stone Brandon , Franzese Ryan , Chavan Sandip , Kinose Fumi , Imbody Denis , Koomen John M. , Rix Uwe , Haura Eric B.
Published: April 2023

Detailed Supplementary Methods
Supplementary Date from ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
Authors: Sharma Sai Kiran , Mack Kyeara N. , Piersigilli Alessandra , Pourat Jacob , Edwards Kimberly J. , Keinänen Outi , Jiao Maria S. , Zhao Huiyong , White Brandy , Brooks Cory L. , de Stanchina Elisa , Madiyalakan Madi R. , Hollingsworth Michael A. , Radhakrishnan Prakash , Lewis Jason S. , Zeglis Brian M.
Published: April 2023

Supplementary Date from ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
Supplementary materials from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Authors: Westin Shannon N. , Labrie Marilyne , Litton Jennifer K. , Blucher Aurora , Fang Yong , Vellano Christopher P. , Marszalek Joseph R. , Feng Ningping , Ma XiaoYan , Creason Allison , Fellman Bryan , Yuan Ying , Lee Sanghoon , Kim Tae-Beom , Liu Jinsong , Chelariu-Raicu Anca , Chen Tsun Hsuan , Kabil Nashwa , Soliman Pamela T. , Frumovitz Michael , Schmeler Katheleen M. , Jazaeri Amir , Lu Karen H. , Murthy Rashmi , Meyer Larissa A. , Sun Charlotte C. , Sood Anil K. , Coleman Robert L. , Mills Gordon B.
Published: April 2023

Supplementary materials
Figure_S7 from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Authors: Westin Shannon N. , Labrie Marilyne , Litton Jennifer K. , Blucher Aurora , Fang Yong , Vellano Christopher P. , Marszalek Joseph R. , Feng Ningping , Ma XiaoYan , Creason Allison , Fellman Bryan , Yuan Ying , Lee Sanghoon , Kim Tae-Beom , Liu Jinsong , Chelariu-Raicu Anca , Chen Tsun Hsuan , Kabil Nashwa , Soliman Pamela T. , Frumovitz Michael , Schmeler Katheleen M. , Jazaeri Amir , Lu Karen H. , Murthy Rashmi , Meyer Larissa A. , Sun Charlotte C. , Sood Anil K. , Coleman Robert L. , Mills Gordon B.
Published: April 2023

Supplementary Figure S7